Medtronic (MDT): Q1 Beat Sparks Target Hikes, but Wall Street Splits on Re-Rating Case
Medtronic plc (NYSE:MDT) drew a broad round of price-target increases after its fiscal 2027 first-quarter results, but Wall Street remains divided over whether accelerating growth can support a meaningful re-rating of the stock. The acceleration follows an earlier debate over whether Medtronic (MDT) is finally becoming a turnaround story. Bull Case: Growth Is Broadening Mizuho […]
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo